Abstract

Aim: This study calculated the opposite capacities of 2 drugs: the erythropoietin (Epo) and the antioxidant drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the platelet crit (PCT) levels alterations, after the respective drug usage in an induced hypoxia reoxygenation animal experiment.

Materials and methods: The 2 main experimental endpoints at which the PCT levels (PCTl) were evaluated were the 60th reoxygenation min (for the groups A, C and E) and the 120th reoxygenation min (for the groups B, D and F). Specially, the groups A and B were processed without drugs, groups C and D after Epo administration; whereas groups E and F after U-74389G administration.

Result: The first preliminary study of Epo non significantly decreased the PCTl by 6.88% ± 3.69% (p-value=0.0615). Also, the second preliminary study of U-74389G non-significantly increased the PCTl by 6.73% ± 37.45% (p-value=0.0712). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has opposite acute effect than Epo (p-value=0.0000).

Conclusion:The anti-oxidant capacities of U-74389G enhance the acute increasing properties on PCTl than epo (p-value=0.0000).

Keywords: Hypoxia; Erythropoietin; U-74389G; Platelet crit; Reoxygenation